Table 4. Propensity score matching analysis for risk factors associated with fatty liver progression.
| Variable | Multivariable | |
|---|---|---|
| HR (95% CI) | P-value | |
| All (N = 512) | ||
| Treatment modality | ||
| Control | 1 (Reference) | |
| Tamoxifen | 1.385 (1.019–1.883) | 0.037 |
| Body mass index (kg/m2) | 1.069 (1.032–1.107) | <0.001 |
| PR (Intermediate or High) | 1.607 (1.186–2.178) | 0.002 |
| Fatty liver (-) at baseline (N = 388) | ||
| Treatment modality | ||
| Control | 1 (Reference) | |
| Tamoxifen | 2.214 (1.416–3.464) | <0.001 |
| Body mass index (kg/m2) | 1.067 (1.014–1.122) | 0.013 |
| Triglyceride | 1.005 (1.002–1.007) | <0.001 |
| Fatty liver (+) at baseline (N = 124) | ||
| Treatment modality | ||
| Control | 1 (Reference) | |
| Tamoxifen | 2.103 (1.156–3.826) | 0.015 |
| Body mass index (kg/m2) | 1.049 (1.005–1.096) | 0.029 |
| HER2 (Intermediate + High) | 1.804 (1.06–3.071) | 0.030 |
| Radiotherapy | 2.081 (1.217–3.56) | 0.007 |
| Total cholesterol | 0.988 (0.981–0.996) | 0.002 |
Abbreviations: HR, hazard ratio; CI, confidence interval.